$12.85 -0.32 (-2.43%)
2/10/2012 4:01 PM

Elan Corp, plc (ADR) (NYSE:ELN)

CAPS Rating: 4 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Featured Broker Partners


Advertisement